Side-by-side comparison of AI visibility scores, market position, and capabilities
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
US YC W20 open-source CBRS private LTE network anyone can deploy at $1.1M revenue 2024; first decentralized cellular network for enterprises/ISPs/individuals competing with Celona for private cellular infrastructure in factories, campuses, and underserved areas.
Ukama is a United States-based decentralized open-source cellular network platform — backed by Y Combinator (W20) — providing enterprises, ISPs, and individuals with the hardware and software to deploy and control their own private LTE-based cellular networks using CBRS (Citizens Broadband Radio Service) spectrum and other bands, generating $1.1 million in annual revenue in 2024 with a 7-person team. Founded in 2020, Ukama positions as the first cellular network that anyone can independently deploy and manage — offering free data within self-deployed coverage areas and global roaming capabilities outside them, enabling use cases from private industrial IoT networks and campus cellular coverage to community-owned internet infrastructure in underserved areas.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.